Results 171 to 180 of about 11,837,096 (346)

Protein binding of vancomycin in a large mixed patient population at a university hospital. [PDF]

Antimicrob Agents Chemother
Dejaco A, Lier C, Krautbauer S, Kees F, Dorn C, Kees MG.   +5 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Editorial: Machine learning in computer-aided drug design

Frontiers in Molecular Biosciences
Ognjen Perišić, Cigdem Sevim Bayrak, Mohamed Khaled Gunady   +2 more
doaj   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Stepwise disassembly of supramolecular structures triggered by specific protein binding. [PDF]

Biophys J
Jia Z, Chen AM, Li S, Thayumanavan S.
europepmc   +1 more source

A protein binding assay for adenosine 3':5'-cyclic monophosphate.

Proceedings of the National Academy of Sciences of the United States of America, 1970
A. Gilman
semanticscholar   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Accurate Identification of Protein Binding Sites for All Drug Modalities Using ALLSites. [PDF]

Adv Sci (Weinh)
Mou M, Lu M, Zhou Z, Ren Y, Yu X, Pan Z, Zhou Y, Yang H, Zheng L, Gu S, Zhang Y, Hu W, Li F, Dai H, Zhu F.   +14 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

PLNet: Persistent Laplacian neural network for protein-protein binding free energy prediction. [PDF]

Protein Sci
Xu X, Wang C, Wei GW, Chen J.
europepmc   +1 more source